ArticleMedical oncology (Northwood, London, England)2026
Dynamic phosphorylation of cGAS by DNA-PKcs and PPP1CC balances DNA repair and innate immunity.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cyclic GMP-AMP synthase (cGAS) is a DNA sensor that localizes to both the cytosol and the nucleus, with dynamic nucleocytoplasmic shuttling. In the cytosol, it drives innate immune signaling upon detecting misplaced self-DNA or foreign DNA. In the nucleus, cGAS is normally tethered to chromatin and catalytically silent, but upon genotoxic stress it is reactivated and engages in DNA damage repair.How cGAS temporally coordinates these dual functions during genotoxic stress remains unresolved. In this study, we identified a context-dependent phosphorylation timer in cells with detectable nuclear cGAS that balances cGAS effects on immune signaling and DNA repair. In G1 phase, cGAS is rapidly phosphorylated by DNA-PKcs after irradiation. This modification suppresses cGAS catalytic activity and delays downstream immune signaling without affecting non-homologous end joining (NHEJ) repair, thereby prioritizing DNA repair over immune activation. Subsequent dephosphorylation by PPP1CC, occurring 8-12 h later, releases cGAS from damage sites and reactivates the cGAS-STING pathway.In S phase, phosphorylated cGAS selectively blocks homologous recombination(HR) while preserving NHEJ. This prevents pathway competition and favors rapid and efficient repair.Later, PPP1CC-mediated dephosphorylation inhibits NHEJ, restores HR competence, and reactivates cGAS catalytic activity. These findings reveal a spatiotemporal mechanism that couples DNA repair progression to immune activation, suggesting that the phosphorylation status of cGAS may inform the therapeutic timing of combined radiotherapy and immunotherapy.
Indexed as
Identifiers
42720700What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.